Aysegül I. M.
- Country
- Austria
- Department
- Department of Medicine I, Divison of Oncology
Research Overview
- Evaluation of Sacituzumab Govitecan in Metastatic Esophagogastric Adenocarcinoma: A Phase Ib/II Single-Arm Multicenter Study
- Phase III Randomized Open-Label Study of Regorafenib and Nivolumab Versus Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer
- Phase 1b/2 Study of S095029 and Pembrolizumab in MSI-H/dMMR Gastroesophageal Junction and Gastric Cancer
Data & Insights
Has run more than one trial at 97 of 267 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced gastroesophageal cancers, with particular emphasis on developing therapeutic approaches for metastatic esophagogastric adenocarcinoma.
- Gastric Cancer Treatment
- Esophageal Cancer Management
- Gastroesophageal Junction Tumors
Their work encompasses both squamous cell carcinoma and adenocarcinoma variants of upper gastrointestinal tract malignancies.
Targeted Therapies
The investigator focuses on novel therapeutic approaches including antibody-drug conjugates and targeted molecular treatments for gastrointestinal cancers.
- HER2-Positive Cancer Treatment
- TROP-2 Targeting Therapies
- Combination Immunotherapy
Their research includes evaluation of multi-modal treatment strategies combining targeted agents with conventional therapies.
Innovative Treatment Approaches
The investigator explores novel therapeutic combinations including the integration of immunochemotherapy with other treatment modalities.
- Advanced Stage Cancer Treatment
- Refractory Disease Management
- Multi-drug Treatment Protocols
Their work includes investigation of selective serotonin reuptake inhibition in combination with cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.